Integrin Blocking Antibodies
Integrin Blocking Antibodies - Related Videos
01:10
Integrins
0 Views •
2023
Animal and protozoan cells do not have cell walls to help maintain shape and provide structural stability. Instead, these eukaryotic cells secrete a sticky mass of carbohydrates and proteins into the spaces between adjacent cells. This network of proteins and molecules is called an extracellular matrix or ECM. Some ECM proteins assemble into a basement membrane to which the remaining components adhere. Proteoglycans typically form the bulk of the ECM while fibrous proteins, like collagen,...
01:15
Activation of Integrins
0 Views •
2023
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling." In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.
13:21
Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples
0 Views •
Cited by 6 •
2012
In this study, we describe an improved protocol for a multiplexed high-throughput antibody microarray with lectin detection method that can be used in glycosylation profiling of specific proteins. This protocol features new reliable reagents and significantly reduces the time, cost, and lab equipment requirements as compared to the previous procedure.
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
0 Views •
Cited by 2 •
2020
We developed a simple flow cytometry assay for evaluating the binding of PD-1–blocking antibodies to T cells, requiring only a drop of peripheral blood from cancer patients.
12:55
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
0 Views •
Cited by 33 •
2015
A method is described with visual accompaniment for conducting scalable, high throughput selections from phage-displayed combinatorial synthetic antibody libraries against hundreds of antigens simultaneously. Using this parallel approach, we have isolated antibody fragments that exhibit high affinity and specificity for diverse antigens that are functional in standard immunoassays.
FAQs
These antibodies can suppress integrin function through at least two mechanisms. They may occupy the receptor’s binding site, preventing interaction with extracellular-matrix proteins or cell-surface ligands, or stabilize an inactive integrin conformation. Either action can reduce outside-in signaling, the transmission of signals into the cell after receptor engagement, thereby limiting adhesion, migration, or cellular activation.
Different integrins support different adhesive interactions and cellular behaviors, so blocking one receptor does not necessarily reproduce the effects of blocking another. The consequences depend on which integrin is targeted and on the tissue context in which it functions. This specificity helps explain why the same general antibody strategy can affect leukocyte movement, platelets, angiogenesis, or tumor-cell behavior differently.
Reducing outside-in signaling can change how cells respond after integrin engagement with a neighboring surface or extracellular-matrix component. The resulting effects may include weaker cell adhesion, reduced migration, and lower cellular activation. These outcomes provide a mechanistic link between receptor blockade and broader processes such as leukocyte trafficking, platelet aggregation, angiogenesis, and tumor-cell behavior.
Experimental use of these antibodies can help identify how integrin-dependent interactions contribute to leukocyte trafficking, angiogenesis, platelet aggregation, and tumor-cell behavior. By interfering with receptor engagement, investigators can examine whether a cellular process depends on adhesion or integrin signaling. The approach therefore connects molecular receptor activity with cell movement, activation, and interactions within tissues.
Clinically developed agents can modulate immune-cell movement or platelet function, making integrin blockade relevant to inflammatory disease and thrombosis. In inflammatory settings, altering immune-cell trafficking may change how leukocytes reach affected tissues. In thrombotic settings, modifying platelet-related integrin activity may influence aggregation. The therapeutic objective depends on the receptor and biological process being targeted.
Results should be interpreted in relation to the targeted integrin, the tissue context, and the process being measured. A reduction in adhesion, migration, or activation may reflect loss of ligand engagement, altered receptor conformation, or decreased outside-in signaling. Comparing these outcomes across leukocytes, platelets, endothelial contexts, or tumor cells can reveal which integrin-dependent function has been affected.